Working… Menu

A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01555242
Recruitment Status : Completed
First Posted : March 15, 2012
Last Update Posted : April 8, 2015
Information provided by (Responsible Party):
Omnitura Therapeutics, Inc.

Brief Summary:
This is a phase I, open-label, multiple dose, dose escalation study to assess the safety, tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally in patients with advanced cancer and lymphomas.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: Aneustat (OMN54) Phase 1

Detailed Description:
Patients who complete a 28-day cycle, may be eligible to continue receiving Aneustat™ (OMN54) in 4-week increments for up to 6 cycles (inclusive of cycle 1) if further treatment is judged to be of possible benefit; if patient has not experienced unacceptable toxicity; and no study withdrawal criteria has been met.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas
Study Start Date : August 2012
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Aneustat (OMN54) Drug: Aneustat (OMN54)
100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of two dosing regimens (once daily and twice daily)
    The maximum tolerated dose (MTD) is defined as the dose, based on data from 6 patients (or 5 patients if one patient has withdrawn due to non-Aneustat (OMN54) related reasons), below the non-tolerated dose (DL T).

  2. Dose Limiting Toxicity (DLT) of two dosing regimens (once daily and twice daily)
    Assessment per Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

  3. Plasma blood concentrations of chemical markers
    These measurements are intended to characterize the pharmacokinetics of Aneustat (OMN54)

Secondary Outcome Measures :
  1. Tumor Response
    Tumor response as per RECIST criteria version 1.1, and tumor markers in plasma, as applicable

  2. Measurement of pathway biomarkers in plasma
    Plasma concentrations of cancer-related proteins to help characterize Aneustat (OMN54) activity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological evidence of malignancy
  • Male or female, 18 years or older
  • Presence of advanced tumours, i.e., measurable or non-measurable disease (RECIST criteria, version 1.1)that have recurred or progressed following standard therapy
  • Able to swallow the oral capsule form of the drug
  • Failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
  • Haematology within 7 days of Day 1 (initial dose):

    • Hemoglobin (Hb) > 9.0 g/dL
    • Platelets ≥ 100,000 cells/mm3 (or, ≥100 x 10/L)
    • Absolute neutrophil count (ANC) > 1.5 cells x109/L (or, > 1500 cells/mm3)
  • Chemistry within 7 days of Day 1 (initial dose):

    • AST(SGOT)/ALT(SGPT) ≤ 2.5 x ULN if no liver metastases, AST(SGOT)/ALT(SGPT) < 5 x ULN if liver metastases
    • Bilirubin < 1.5 x ULN unless Gilbert's Syndrome
    • Serum creatinine ≤ 1.25 ULN
  • Coagulation within 7 days of Day 1 (initial dose):

    *INR ≤ 1.5

  • ECOG Performance Status between 0 - 2 and estimated life expectancy of > 3 months.
  • Having the initiative and means to be compliant with the protocol (as judged by the Principal Investigator) and is within a feasible geographical proximity of the study center to make the required study visits.
  • Written informed consent obtained prior to any study screening procedures
  • Females of childbearing potential (a female is considered of childbearing potential unless she is postmenopausal, i.e., no menses for at least 12 consecutive months, or is without a uterus) must have a negative urine pregnancy test (UPT) within 7 days of Day 1 (initial dose)
  • Females of childbearing potential must agree to use an effective method of contraception (i.e., sexual abstinence, condoms, intrauterine device, diaphragm) from Screening period and throughout study participation.

Exclusion Criteria:

  • Patient has uncontrolled or symptomatic brain metastases (If a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days prior to Day 1 dosing).
  • Use of an investigational medication or device within 30 days of initiating study therapy (Day 1).
  • Major surgery within 30 days prior to first dose (Day 1).
  • Radiotherapy, chemotherapy, or immunotherapy within 28 days prior to Day 1 (not including palliative radiotherapy at focal sites).
  • Pregnancy or lactation.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NY Heart Association Class III or IV, see Appendix 3), unstable angina pectoris, unstable cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements.
  • Screening (within approximately 28 days of registration) 12-lead electrocardiogram (ECG) that is abnormal and clinically significant
  • Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.
  • Use of warfarin, i.e., Coumadin®, Jantoven® within 7 days prior to Day 1 (initial dosing)
  • Intolerance or aversion to porcine ingredients that are used for the OMN54 oral capsules in the investigational medicine, OMN54 (Aneustat™).
  • Known hypersensitivity to any of the three botanical constituents of Aneustat™ (OMN54), or other similar plants; or to plants belonging to Labiatae or Lamiaceae families, soy, or Aneustat™ (OMN54) excipients
  • Use of Sophora subprostrata root (SSR) or herba serissae within 14 days prior to Day 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01555242

Layout table for location information
Canada, British Columbia
BC Cancer Agency-Vancouver Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Sponsors and Collaborators
Omnitura Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Omnitura Therapeutics, Inc. Identifier: NCT01555242     History of Changes
Other Study ID Numbers: OMN54-101
First Posted: March 15, 2012    Key Record Dates
Last Update Posted: April 8, 2015
Last Verified: April 2015
Keywords provided by Omnitura Therapeutics, Inc.:
Advanced Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases